The prognosis for patients with relapsed/refractory multiple myeloma (MM) is usually poor. In this video, Francesca Gay, MD, from the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy, discusses the results from a Phase Ib/II clinical trial (NCT02056756), which explored the efficacy of a combination carfilzomib, dexamethasone and bendamustine (KBd) therapy in heavily pre-treated relapsed MM patients. While this treatment regimen was effective, Dr Gay discusses the issues associated with treating such a high-risk patient group, including the necessity for infection prophylaxis to address lymphopenia. This interview took place at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
